BACKGROUND AND AIM: Reflux symptoms in patients with non-erosive reflux disease (NERD) cannot be easily controlled by treatment with proton pump inhibitors (PPI). The anti-inflammatory function of rebamipide may be effective for protecting the esophageal mucosa. This prospective randomized multicenter placebo-controlled study was performed to clarify the efficacy of rebamipide for NERD patients whose reflux symptoms were refractory to PPI treatment. METHODS:One hundred forty-nine patients were enrolled on the basis of a QUEST score of over 6 and absence of endoscopically proven esophageal mucosal breaks. All the patients were initially administered 15 mg of lansoprazole for 4 weeks, and the symptoms were then assessed using QUEST and GSRS. PPI-refractory patients were randomly assigned to administration of rebamipide or placebo t.i.d. for 4 weeks. RESULTS: Three of the 149 patients were lost to follow-up, and 60 among the remaining 146 patients were found to be PPI-refractory. Among these PPI-refractory patients, 31 were randomly assigned to a rebamipide group and 29 to a placebo group. At the end of drug administration, the QUEST and GSRS scores did not differ between the rebamipide and placebo groups, although a significantly higher proportion of patients in the rebamipide group showed amelioration of abdominal pain and diarrhea. CONCLUSION: Administration of rebamipide cannot effectively control reflux symptoms in NERD patients whose symptoms are refractory to PPI therapy.
RCT Entities:
BACKGROUND AND AIM: Reflux symptoms in patients with non-erosive reflux disease (NERD) cannot be easily controlled by treatment with proton pump inhibitors (PPI). The anti-inflammatory function of rebamipide may be effective for protecting the esophageal mucosa. This prospective randomized multicenter placebo-controlled study was performed to clarify the efficacy of rebamipide for NERD patients whose reflux symptoms were refractory to PPI treatment. METHODS: One hundred forty-nine patients were enrolled on the basis of a QUEST score of over 6 and absence of endoscopically proven esophageal mucosal breaks. All the patients were initially administered 15 mg of lansoprazole for 4 weeks, and the symptoms were then assessed using QUEST and GSRS. PPI-refractory patients were randomly assigned to administration of rebamipide or placebo t.i.d. for 4 weeks. RESULTS: Three of the 149 patients were lost to follow-up, and 60 among the remaining 146 patients were found to be PPI-refractory. Among these PPI-refractory patients, 31 were randomly assigned to a rebamipide group and 29 to a placebo group. At the end of drug administration, the QUEST and GSRS scores did not differ between the rebamipide and placebo groups, although a significantly higher proportion of patients in the rebamipide group showed amelioration of abdominal pain and diarrhea. CONCLUSION: Administration of rebamipide cannot effectively control reflux symptoms in NERD patients whose symptoms are refractory to PPI therapy.
Authors: C M Bate; J R Green; A T Axon; F E Murray; G Tildesley; C E Emmas; M D Taylor Journal: Aliment Pharmacol Ther Date: 1997-08 Impact factor: 8.171
Authors: F Moki; M Kusano; M Mizuide; Y Shimoyama; O Kawamura; H Takagi; T Imai; M Mori Journal: Aliment Pharmacol Ther Date: 2007-10-01 Impact factor: 8.171
Authors: R Carlsson; J Dent; E Bolling-Sternevald; F Johnsson; O Junghard; K Lauritsen; S Riley; L Lundell Journal: Scand J Gastroenterol Date: 1998-10 Impact factor: 2.423
Authors: E S Lee; N Kim; S H Lee; Y S Park; J W Kim; S H Jeong; D H Lee; H C Jung; I S Song Journal: Aliment Pharmacol Ther Date: 2009-04-15 Impact factor: 8.171
Authors: H Miwa; M Sasaki; T Furuta; T Koike; Y Habu; M Ito; Y Fujiwara; T Wada; A Nagahara; M Hongo; T Chiba; Y Kinoshita Journal: Aliment Pharmacol Ther Date: 2007-07-01 Impact factor: 8.171